Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 plus pembrolizumab versus pembrolizumab in previously untreated advanced melanoma
2021-004594-32Phase 3Active
- Sponsor
- IO Biotech
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing IO102-IO103 plus pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Progression-free survival. Started Dec 2021; status: active.
02
Drugs
PD-L1/IDO peptide vaccinepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2021-004594-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004594-32.